Noramco presented testimony and answered questions at the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing.
Noramco and Willow Biosciences Announce Joint Development of Biosynthesis Platform for Cannabidiol
Noramco and Willow Biosciences Inc. today announced they have entered into an exclusive Joint Development Agreement (“JDA”) to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol.
Nemus Bioscience Signs Agreement with Noramco
Nemus Bioscience announced an agreement with Noramco for the manufacturing and scale-up of proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi.
Noramco at AAPS 2018
Noramco is participating in the Scientific Thought Leadership program at this year’s AAPS. Dr. Wen-Chun Zhang will be presenting a Chalk Talk on the topic of “The New Era of Ultra-Pure Synthetic Cannabinoids” on Tuesday, November 6th, 2018 from 10:30 am to 10:50.
Noramco Adds Capacity and Dual Sources of Supply for Cannabinoids
Noramco, a leader in controlled substances and cannabinoids, is adding commercial-scale capacity of dronabinol (THC) at its Athens, Georgia, United States facility. The expansion comes in response to rising demand for its highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.
Noramco Announces Provisional Patent Application of Proprietary Cannabidiol (CBD)
Noramco, a global leading producer of controlled substances, including cannabinoids for the pharmaceutical industry, today announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) directed to its proprietary pure cannabidiol (CBD) compositions.
Noramco and SPI Pharma sign agreement to develop ready-to-implement, patient-friendly formulations for pharmaceutical manufacturers
Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers…
Noramco adds 23 compounds to analytical reference standards catalogue
Noramco announced the addition of 23 new compounds to its analytical reference standards catalog – compounds pharmaceutical product developers require to validate product quality and to verify the integrity of production systems…
Noramco, Inc. and AMPAC Fine Chemicals Announce Strategic Partnership In Scheduled Pharmaceutical Ingredients
Noramco, Inc., a global leading producer of controlled substances for the pharmaceutical industry, and AMPAC Fine Chemicals (AFC), a major manufacturer of Active Pharmaceutical Ingredients…
- 1
- 2